Reference Type:  Journal Article
Record Number: 1039
Author: Anderson, D. C. and Kodukula, K.
Year: 2014
Title: Biomarkers in pharmacology and drug discovery
Journal: Biochemical Pharmacology
Volume: 87
Issue: 1
Pages: 172-188
Short Title: Biomarkers in pharmacology and drug discovery
ISSN: 00062952 (ISSN)
DOI: 10.1016/j.bcp.2013.08.026
Keywords: Biomarkers
Disease diagnosis biomarker discovery
Polypharmacy
Protein biomarkers
antineoplastic agent
B Raf kinase
BCR ABL protein
biological marker
BRCA1 protein
BRCA2 protein
cetuximab
crizotinib
dasatinib
epidermal growth factor receptor
epidermal growth factor receptor 2
erlotinib
gefitinib
imatinib
nilotinib
olaparib
panitumumab
promyelocytic leukemia protein
retinoic acid
retinoic acid receptor
tamoxifen
trastuzumab
veliparib
vemurafenib
bioinformatics
clinical pathway
clinical pharmacology
clinical practice
data analysis
drug development
drug targeting
genetic association
human
information processing
liquid chromatography
mass spectrometry
matrix assisted laser desorption ionization time of flight mass spectrometry
metabolomics
nonhuman
priority journal
proteomics
randomized controlled trial (topic)
reproducibility
review
statistical analysis
study design
surface enhanced laser desorption ionization time of flight mass spectrometry
tandem mass spectrometry
validation process
Alzheimer Disease
Animals
Biological Markers
Drug Discovery
Humans
Neoplasms
Pharmacology
Abstract: Biomarkers, quantitatively measurable indicators of biological or pathogenic processes, once validated play a critical role in disease diagnostics, the prediction of disease progression, and/or monitoring of the response to treatment. They may also represent drug targets. A number of different methods can be used for biomarker discovery and validation, including proteomics methods, metabolomics, imaging, and genome wide association studies (GWASs) and can be analysed using receiver operating characteristic (ROC) plots. The relative utility of single biomarkers compared to biomarker panels is discussed, along with paradigms for biomarker development, the latter in the context of three large-scale biomarker consortia, the Critical Path Predictive Safety Testing Consortium (PSTC), the NCI Early Detection Research Network (EDRN) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). The importance of systematic optimization of many parameters in biomarker analysis, including validation, reproducibility, study design, statistical analysis and avoidance of bias are critical features used by these consortia. Problems including introduction of bias into study designs, data reporting or data analysis are also reviewed. © 2013 Elsevier Inc.
Notes: Cited By (since 1996):7
Export Date: 28 May 2014
Source: Scopus
CODEN: BCPCA
PubMed ID: 24001556
Language of Original Document: English
Correspondence Address: Anderson, D.C.; Center for Advanced Drug Research, SRI International, Harrisonburg, VA 22802, United States; email: dave.anderson@sri.com
Chemicals/CAS: cetuximab, 205923-56-4; crizotinib, 877399-52-5; dasatinib, 302962-49-8, 863127-77-9; epidermal growth factor receptor, 79079-06-4; epidermal growth factor receptor 2, 137632-09-8; erlotinib, 183319-69-9, 183321-74-6; gefitinib, 184475-35-2, 184475-55-6, 184475-56-7; imatinib, 152459-95-5, 220127-57-1; nilotinib, 641571-10-0; olaparib, 763113-22-0; panitumumab, 339177-26-3; retinoic acid, 302-79-4; tamoxifen, 10540-29-1; trastuzumab, 180288-69-1; veliparib, 912444-00-9; vemurafenib, 918504-65-1
References: Poste, G., Bring on the biomarkers (2011) Nature, 469, pp. 156-157; Rifai, N., Gillette, M.A., Carr, S.A., Protein biomarker discovery and validation: The long and uncertain path to clinical utility (2006) Nature Biotechnology, 24 (8), pp. 971-983. , DOI 10.1038/nbt1235, PII NBT1235; Cummings, J., Raynaud, F., Jones, L., Sugar, R., Dive, C., Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs (2010) Br J Cancer, 103, pp. 1313-1317. , On behalf of the Bioanalysis and Quality Assurance (BAQA) Group of the ECMC; Puntmann, V., How-to guide on biomarkers: Biomarker definitions, validation and applications with examples from cardiovascular disease (2009) Postgrad Med J, 85, pp. 538-545; Szekely-Klepser, G., Fountain, S., Validation of biochemical biomarker assays used in drug discovery and development: A review of challenges and solutions (2012) Predictive Approaches in Drug Discovery and Development: Biomarkers and in Drug Discovery and Development, pp. 23-48. , J. Williams, J.A. Lalonde, R. Koup, J.R.D.D. Christ, Wiley Hoboken; Flood, D., Marek, G., Williams, M., Developing predictive CSF biomarkers - A challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine (2011) Biochem Pharmacol, 81, pp. 1422-1434; Paweletz, C.P., Andersen, J.N., Pollock, R., Nagashima, K., Hayashi, M.L., Identification of direct target engagement biomarkers for kinase-targeted therapeutics (2011) PLoS ONE, 6, p. 26459; Atkinson, A.J., Colburn, W.A., DeGruttola, V.G., DeMets, D.L., Downing, G.J., Hoth, D.F., Oates, J.A., Zeger, S.L., Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework (2001) Clinical Pharmacology and Therapeutics, 69 (3), pp. 89-95. , DOI 10.1067/mcp.2001.113989; Frank, R., Hargreaves, R., Clinical biomarkers in drug discovery and development (2003) Nature Reviews Drug Discovery, 2 (7), pp. 566-580; Dancey, J.E., Dobbin, K.K., Groshen, S., Jessup, J.M., Hruszkewycz, A.H., Koehler, M., Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents (2010) Clin Cancer Res, 16, pp. 1745-1755; Oldenhuis, C., Oosting, S., Gietema, J., De Vries, E., Prognostic versus predictive value of biomarkers in oncology (2008) Eur J Cancer, 44, pp. 946-953; Rausch, L., Green, C., Steinmetz, K., Levalley, S., Catz, P., Zaveri, N., Preclinical pharmacokinetic toxicological and biomarker evaluation of SR 16157, a novel dual-acting steroid sulfatase inhibitor and selective estrogen receptor modulator (2011) Cancer Chemother Pharmacol, 67, pp. 1341-1352; Canick, J.A., Kloza, E.M., Lambert-Messerlian, G.M., Haddow, J.E., Ehrich, M., Van Den Boom, D., DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations (2012) Prenat Diagn, 32, pp. 730-734; Xi, R., Kim, T.-M., Park, P., Detecting structural variations in the human genome using next generation sequencing (2011) Briefings Funct Genomics, 9, pp. 405-415; Riedmaier, I., Pfaffl, M., Transcriptional biomarkers - High throughput screening, quantitative verification, and bioinformatical validation methods (2013) Methods, 59, pp. 3-9; Ahlquist, D.A., Zou, H., Domanico, M., Mahoney, D.W., Yab, T.C., Taylor, W.R., Next-generation stool DNA test accurately detects colorectal cancer and large adenomas (2012) Gastroenterology, 142, pp. 248-256; Nikas, J.B., Low, W.C., Linear discriminant functions in connection with the micro-RNA diagnosis of colon cancer (2012) Cancer Inf, 11, pp. 1-14; Thal, L.J., Kantarci, K., Reiman, E.M., Klunk, W.E., Weiner, M.W., Zetterberg, H., Galasko, D., Siemers, E., The role of biomarkers in clinical trials for Alzheimer disease (2006) Alzheimer Disease and Associated Disorders, 20 (1), pp. 6-15. , DOI 10.1097/01.wad.0000191420.61260.a8, PII 0000209320060100000003; Klassen, B.T., Hentz, J.G., Shill, H.A., Driver-Dunckley, E., Evidente, V.G., Sabbagh, M.N., Quantitative EEG as a predictive biomarker for Parkinson disease dementia (2011) Neurology, 77, pp. 118-124; Yu, P., Dean, R.A., Hall, S.D., Qi, Y., Sethuraman, G., Willis, B.A., Enriching amnestic mild cognitive impairment populations for clinical trials: Optimal combination of biomarkers to predict conversion to dementia (2012) J Alzheimers Dis, 32, pp. 373-385; Bain, G., Petty, R., Predicting response to treatment in gastroesophageal junction adenocarcinomas: Combining clinical, imaging, and molecular biomarkers (2010) The Oncologist, 15, pp. 270-284; Schoonenboom, N.S.M., Van Der Flier, W.M., Blankenstein, M.A., Bouwman, F.H., Van Kamp, G.J., Barkhof, F., Scheltens, P., CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease (2008) Neurobiology of Aging, 29 (5), pp. 669-675. , DOI 10.1016/j.neurobiolaging.2006.11.018, PII S0197458006004404; Zhang, D., Wang, Y., Zhou, L., Yuan, H., Shen, D., Multimodal classification of Alzheimer's disease and mild cognitive impairment (2011) NeuroImage, 55, pp. 856-867. , the Alzheimer's Disease Neuroimaging Initiative 1; Shtilbans, A., Henchcliffe, C., Biomarkers in Parkinson's disease: An update (2012) Curr Opin Neurol, 25, pp. 460-465; Lonn, E., The use of surrogate endpoints in clinical trials: Focus on clinical trials in cardiovascular diseases (2001) Pharmacoepidemiology and Drug Safety, 10 (6), pp. 497-508. , DOI 10.1002/pds.654; Heinonen, T.M., Aamer, M., Marshall, C., Black, D.M., Tardif, J.C., Cardiovascular biomarkers and surrogate end points: Key initiatives and clinical trial challenges (2012) Expert Rev Cardiovasc Ther, 10, pp. 989-994; Nathan, D.M., Balkau, B., Bonora, E., Borch-Johnsen, K., Buse, J.B., Colagiuri, S., International expert committee report on the role of the A1C assay in the diagnosis of diabetes (2009) Diab Care, 32, pp. 1327-1334; Buyse, M., Sargent, D.J., Grothey, A., Matheson, A., De Gramont, A., Biomarkers and surrogate end points- the challenge of statistical validation (2009) Nat Rev Clin Oncol, 7, pp. 309-317; Rosenberg, E., Baniel, J., Spector, Y., Faerman, A., Meiri, E., Aharonov, R., Predicting progression of bladder urothelial carcinoma using microRNA expression (2013) BJU Int, , FEB 6 epub; Goncalves, R., Bose, R., Using multigene tests to select treatment for early-stage breast cancer (2013) J Natl Compr Canc Netw, 11, pp. 174-182; Markopoulos, C., Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer (2013) Expert Rev Anticancer Ther, 13, pp. 179-194; Jelovac, D., Wolff, A.C., The adjuvant treatment of HER2-positive breast cancer (2012) Curr Treat Options Oncol, 13, pp. 230-239; Bang, Y.J., Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer (2012) J Clin Gastroenterol, 46, pp. 637-648; McAlpine, J.N., Wiegand, K.C., Vang, R., Ronnett, B.M., Adamiak, A., Köbel, M., HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy (2009) BMC Cancer, 9, p. 433; Schilsky, R.L., Personalized medicine in oncology: The future is now (2010) Nat Rev Drug Discov, 9 (363), p. 366; Beelen, K., Zwart, W., Linn, S.C., Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? (2012) Nat Rev Clin Oncol, 9, pp. 529-541; Ali, S., Coombes, R.C., Estrogen receptor alpha in human breast cancer: Occurrence and significance (2000) Journal of Mammary Gland Biology and Neoplasia, 5 (3), pp. 271-281. , DOI 10.1023/A:1009594727358; Ross, J.S., Symmans, W.F., Pusztai, L., Hortobagyi, G.N., Standardizing slide-based assays in breast cancer: Hormone receptors, HER2, and sentinel lymph nodes (2007) Clinical Cancer Research, 13 (10), pp. 2831-2835. , DOI 10.1158/1078-0432.CCR-06-2522; Lopez-Chavez, A., Giaccone, G., Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer (2010) Nat Rev Clin Oncol, 7, pp. 360-362; Ciardiello, F., Tortora, G., EGFR antagonists in cancer treatment (2008) N Engl J Med, 358, pp. 1160-1174; Jackman, D.M., Miller, V.A., Cioffredi, L.A., Yeap, B.Y., Janne, P.A., Riely, G.J., Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials (2009) Clin Cancer Res, 15, pp. 5267-5273; Lopez-Rios, F., Angulo, B., Gomez, B., Mair, D., Martinez, R., Conde, E., Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer (2013) J Clin Pathol, 66, pp. 381-385; Linardou, H., Dahabreh, I.J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer (2008) Lancet Oncol, 9, pp. 962-972; Hutchinson, L., Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations (2010) Nat Rev Clin Oncol, 7, p. 549; Begg, C.B., Haile, R.W., Borg, A., Malone, K.E., Concannon, P., Thomas, D.C., Variation of breast cancer risk among BRCA1/2 carriers (2008) JAMA, 299, pp. 194-201; Deininger, M.W.N., Druker, B.J., Specific targeted therapy of chronic myelogenous leukemia with imatinib (2003) Pharmacological Reviews, 55 (3), pp. 401-423. , DOI 10.1124/pr.55.3.4; Terasawa, T., Dahabreh, I., Trikalinos, T., BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (2010) PLoS Curr, 2, p. 1204; Diverio, D., Riccioni, R., Mandelli, F., Lo Coco, F., The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia (1995) Haematologica, 80, pp. 155-160; Wang, Z.Y., Chen, Z., Acute promyelocytic leukemia: From highly fatal to highly curable (2008) Blood, 111, pp. 2505-2515; Reiter, A., Lengfelder, E., Grimwade, D., Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia (2004) Acta Haematologica, 112 (1-2), pp. 55-67. , DOI 10.1159/000077560; Gajria, D., Chandarlapaty, S., HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies (2011) Expert Rev Anticancer Ther, 11, pp. 263-275; Cuadros, M., Villegas, M., Systematic review of HER2 breast cancer testing (2009) Appl Immunohistochem Mol Morphol, 17, p. 107; Smalley, K.S., Sondak, V.K., Melanoma - An unlikely poster child for personalized cancer therapy (2010) N Engl J Med, 363, pp. 876-878; Ong, F., Das, K., Wang, J., Vakil, H., Kuo, J., Wendell-Lamar, B., Personalized medicine and pharmacogenetic biomarkers (2012) Expert Rev Molec Diag, 12, pp. 593-602; Martelli, M.P., Sozzi, G., Hernandez, L., Pettirossi, V., Navarro, A., Conte, D., EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues (2009) Am J Pathol, 174, pp. 661-670; Shaw, A.T., Solomon, B., Kenudson, M.M., Crizotinib and testing for ALK (2011) J Natl Compr Canc Netw, 9, pp. 1335-1341; La Thangue, N., Kerr, D., Predictive biomarkers: A paradigm shift towards personalized cancer medicine (2011) Nat Rev Clin Oncol, 8, pp. 587-596; Rix, U., Superti-Furga, G., Target profiling of small molecules by chemical proteomics (2009) Nat Chem Biol, 5, pp. 616-624; Rix, U., Hantschel, O., Durnberger, G., Remsing Rix, L.L., Planyavsky, M., Fernbach, N.V., Kaupe, I., Superti-Furga, G., Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets (2007) Blood, 110 (12), pp. 4055-4063. , http://bloodjournal.hematologylibrary.org/cgi/reprint/110/12/4055, DOI 10.1182/blood-2007-07-102061; Talpaz, M., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., Sawyers, C.L., Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias (2006) New England Journal of Medicine, 354 (24), pp. 2531-2541. , http://content.nejm.org/cgi/reprint/354/24/2531.pdf, DOI 10.1056/NEJMoa055229; Brehmer, D., Greff, Z., Godl, K., Blencke, S., Kurtenbach, A., Cellular targets of gefitinib (2005) Cancer Res, 65, pp. 379-382; Zhang, L., Gjoerup, O., Roberts, T.M., The serine/threonine kinase cyclin G-associated kinase regulates epidermal growth factor receptor signaling (2004) Proceedings of the National Academy of Sciences of the United States of America, 101 (28), pp. 10296-10301. , DOI 10.1073/pnas.0403175101; Prensner, J.R., Chinnaiyan, A., Srivastava, S., Systematic, evidence-based discovery of biomarkers at the NCI (2012) Clin Exp Metastasis, 29, pp. 645-652; Voskoglou-Nomikos, T., Pater, J.L., Seymour, L., Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models (2003) Clinical Cancer Research, 9 (11), pp. 4227-4239; McGonigle, P., Ruggeri, B.A., Animal Models of Human Disease: Challenges in enabling translation (2014) Biochem Pharmacol, 87, pp. 162-171; Day, M., Balci, F., Wan, H.I., Fox, G.B., Rutkowski, J.L., Feuerstein, G., Cognitive endpoints as disease biomarkers: Optimizing the congruency of preclinical models to the clinic (2008) Current Opinion in Investigational Drugs, 9 (7), pp. 696-706; Nestler, E.J., Hyman, S.E., Animal models of neuropsychiatric disorders (2010) Nat Neurosci, 13, pp. 1161-1169; McGonigle, P., Animal Models of CNS disorders (2014) Biochem Pharmacol, 87, pp. 140-149; Diamandis, E., Cancer biomarkers: Can we turn recent failures into success? (2010) J Natl Cancer Inst, 102, pp. 1462-1467; Pendyala, G., Trauger, S.A., Kalisiak, E., Ellis, R.J., Siuzdak, G., Fox, H.S., Cerebrospinal fluid proteomics reveals potential pathogenic changes in the brains of SIV-infected monkeys (2009) J Proteome Res, 8, pp. 2253-2260; Liang, C.R., Tan, S., Tan, H.T., Lin, Q., Lim, T.K., Liu, Y., Proteomic analysis of human gastric juice: A shotgun approach (2010) Proteomics, 10, pp. 3928-3931; Elashoff, D., Zhou, H., Reiss, J., Wang, J., Xiao, H., Henson, B., Prevalidation of salivary biomarkers for oral cancer detection (2012) Cancer Epidemiol Biomarkers Prev, 21, pp. 664-672; Fehlbaum-Beurdeley, P., Jarrige-Le Prado, A.C., Pallares, D., Carrière, J., Guihal, C., Soucaille, C., Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression (2010) Alzheimers Dement, 6, pp. 25-38; Tuck, M.K., Chan, D.W., Chia, D., Godwin, A.K., Grizzle, W.E., Krueger, K.E., Standard operating procedures for serum and plasma collection: Early detection research network consensus statement standard operating procedure integration working group (2009) J Proteome Res, 8, pp. 113-117; Addona, T., Shi, X., Keshishian, H., Mani, D., Burgess, M., Gillette, M., A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease (2011) Nat Biotechnol, 29, pp. 635-653; Wallstrom, G., Anderson, K.S., Labaer, J., Biomarker discovery for heterogeneous diseases (2013) Cancer Epidemiol Biomarkers Prev, 22, pp. 747-755; Villeda, S.A., Luo, J., Mosher, K.I., Zou, B., Britschgi, M., Bieri, G., The ageing systemic milieu negatively regulates neurogenesis and cognitive function (2011) Nature, 477, pp. 90-94; Yang, X., Lazar, I.M., MRM screening/biomarker discovery with linear ion trap MS: A library of human cancer-specific peptides (2009) BMC Cancer, 9, p. 96; Liu, B.C., Dijohnson, D.A., O'Rourke, D.J., Antibody profiling with protein antigen microarrays in early stage cancer (2012) Expert Opin Med Diagn, 6, pp. 187-196; Oka, S., Furukawa, H., Shimada, K., Hayakawa, H., Fukui, N., Tsuchiya, N., Serum biomarker analysis of collagen disease patients with acute-onset diffuse interstitial lung disease (2013) BMC Immunol, 14, p. 9; Wolters, D.A., Washburn, M.P., Yates III, J.R., An automated multidimensional protein identification technology for shotgun proteomics (2001) Analytical Chemistry, 73 (23), pp. 5683-5690. , DOI 10.1021/ac010617e; Hunt, D.F., Yates III, J.R., Shabanowitz, J., Protein sequencing by tandem mass spectrometry (1986) Proceedings of the National Academy of Sciences of the United States of America, 83 (17), pp. 6233-6237. , DOI 10.1073/pnas.83.17.6233; Dayon, L., Pasquarello, C., Hoogland, C., Sanchez, J.C., Scherl, A., Combining low- and high-energy tandem mass spectra for optimized peptide quantification with isobaric tags (2010) J Proteomics, 73, pp. 769-777; Ong, S.E., Blagoev, B., Kratchmarova, I., Kristensen, D.B., Steen, H., Pandey, A., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics (2002) Mol Cell Proteomics, 1, pp. 376-386; Gonzalez-Galarza, F., Lawless, C., Hubbard, S., Fan, J., Bessant, C., Hermjakob, H., A critical appraisal of techniques, software packages, and standards for quantitative proteomic analysis (2012) J Integrative Biol, 16, pp. 431-442; Ishihama, Y., Oda, Y., Tabata, T., Sato, T., Nagasu, T., Rappsilber, J., Mann, M., Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein (2005) Molecular and Cellular Proteomics, 4 (9), pp. 1265-1272. , DOI 10.1074/mcp.M500061-MCP200; Lundgren, D.H., Hwang, S.I., Wu, L., Han, D.K., Role of spectral counting in quantitative proteomics (2010) Exp Rev Proteomics, 7, pp. 39-53; Michalski, A., Damoc, E., Hauschild, J.P., Lange, O., Wieghaus, A., Makarov, A., Mass spectrometry- based proteomics using Q exactive, a high-performance benchtop quadrupole orbitrap mass spectrometer (2011) Mol Cell Proteomics, 10 (M111), p. 011015; Geiger, T., Madden, S., Gallagher, W., Cox, J., Mann, M., Proteomic portrait of human breast cancer progression identifies novel prognostic markers (2012) Cancer Res, 72, pp. 2428-2439; Geiger, T., Wehner, A., Schaab, C., Cox, J., Mann, M., Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins (2012) Mol Cell Proteomics, 11 (M111), p. 014050; Hutchins, T.W., Yip, T.T., New desorption strategies for the mass spectrometric analysis of macromolecules (1993) Rapid Commun Mass Spectrom, 7, p. 576; Albrethsen, J., The first decade of MALDI protein profiling: A lesson in translational biomarker research (2011) J Proteomics, 74, pp. 765-773; Diamandis, E.P., Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitations (2004) Molecular and Cellular Proteomics, 3 (4), pp. 367-378. , DOI 10.1074/mcp.R400007-MCP200, Cancer Proteomics; Karpova, M.A., Moshkovskii, S.A., Toropygin, I.Y., Archakov, A.I., Cancer-specific MALDI-TOF profiles of blood serum and plasma: Biological meaning and perspectives (2010) J Proteomics, 73, pp. 537-551; Krause, E., Wenschuh, H., Jungblut, P.R., The dominance of arginine-containing peptides in MALDI-derived tryptic mass fingerprints of proteins (1999) Analytical Chemistry, 71 (19), pp. 4160-4165. , DOI 10.1021/ac990298f; Schlosser, G., Pocsfalvi, G., Huszar, E., Malorni, A., Hudecz, F., MALDI-TOF mass spectrometry of a combinatorial peptide library: Effect of matrix composition on signal suppression (2005) Journal of Mass Spectrometry, 40 (12), pp. 1590-1594. , DOI 10.1002/jms.937; Ekblad, L., Baldetorp, B., Ferno, M., Olsson, H., Bratt, C., In-source decay causes artifacts in SELDI-TOF MS spectra (2007) Journal of Proteome Research, 6 (4), pp. 1609-1614. , DOI 10.1021/pr060633y; Baggerly, K.A., Morris, J.S., Edmonson, S.R., Coombes, K.R., Signal in noise: Evaluating reported reproducibility of serum proteomic tests for ovarian cancer (2005) Journal of the National Cancer Institute, 97 (4), pp. 307-309. , DOI 10.1093/jnci/dji008; Xu, R., Gamst, A., Lessons from controversy: Ovarian cancer screening and serum proteomics (2005) J Natl Cancer Inst, 97, p. 1227. , 1226; author reply; Ransohoff, D.F., Lessons from controversy: Ovarian cancer screening and serum proteomics (2005) Journal of the National Cancer Institute, 97 (4), pp. 315-319. , DOI 10.1093/jnci/dji054; Albrethsen, J., Reproducibility in protein profiling by MALDI-TOF mass spectrometry (2007) Clinical Chemistry, 53 (5), pp. 852-858. , DOI 10.1373/clinchem.2006.082644; Albrethsen, J., Bogebo, R., Olsen, J., Raskov, H., Gammeltoft, S., Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum (2006) Clinical Chemistry and Laboratory Medicine, 44 (10), pp. 1243-1252. , DOI 10.1515/CCLM.2006.228, PII CCLM44101243; Zou, J., Hong, G., Guo, X., Zhang, L., Yao, C., Wang, J., Reproducible cancer biomarker discovery in SELDI-TOF MS using different pre-processing algorithms (2011) PLoS One, 6, p. 26294; Szájli, E., Fehér, T., Medzihradszky, K.F., Investigating the quantitative nature of MALDI-TOF MS (2008) Mol Cell Proteomics, 7, pp. 2410-2418; Petricoin III, E.F., Ardekani, A.M., Hitt, B.A., Levine, P.J., Fusaro, V.A., Steinberg, S.M., Mills, G.B., Liotta, L.A., Use of proteomic patterns in serum to identify ovarian cancer (2002) Lancet, 359 (9306), pp. 572-577. , DOI 10.1016/S0140-6736(02)07746-2; McLerran, D., Grizzle, W.E., Feng, Z., Bigbee, W.L., Banez, L.L., Cazares, L.H., Chan, D.W., Semmes, O.J., Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: Sources of sample bias (2008) Clinical Chemistry, 54 (1), pp. 44-52. , http://www.clinchem.org/cgi/reprint/54/1/44, DOI 10.1373/clinchem.2007.091470; McLerran, D., Grizzle, W.E., Feng, Z., Thompson, I.M., Bigbee, W.L., Cazares, L.H., Chan, D.W., Semmes, O.J., SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer (2008) Clinical Chemistry, 54 (1), pp. 53-60. , http://www.clinchem.org/cgi/reprint/54/1/53, DOI 10.1373/clinchem.2007.091496; Putri, S., Yamamoto, S., Tsugawa, H., Fukusaki, E., Current metabolomics: Technological advances (2013) J Biosci Bioeng, 116, pp. 9-16; Ramautar, R., Somsen, G.W., De Jong, G.J., CE-MS for metabolomics: Developments and applications in the period 2010-2012 (2013) Electrophoresis, 34, pp. 86-98; Mandal, R., Guo, A.C., Chaudhary, K.K., Liu, P., Yallou, F.S., Dong, E., Multi-platform characterization of the human cerebrospinal fluid metabolome: A comprehensive and quantitative update (2012) Genome Med, 4, p. 38; Boots, A.W., Van Berkel, J.J., Dallinga, J.W., Smolinska, A., Wouters, E.F., Van Schooten, F.J., The versatile use of exhaled volatile organic compounds in human health and disease (2012) J Breath Res, 6, p. 027108; Smolinska, A., Blanchet, L., Buydens, L.M., Wijmenga, S.S., NMR and pattern recognition methods in metabolomics: From data acquisition to biomarker discovery: A review (2012) Anal Chim Acta, 750, pp. 82-97; Theodoridis, G., Gika, H., Want, E., Wilson, I., Liquid chromatography-mass spectrometry based global metabolite profiling: A review (2012) Anal Chim Acta, 711, pp. 7-16; Park, Y., Lee, K., Soltow, Q., Strobel, F., Brigham, K., Parker, R., High-performance metabolic profiling of plasma from seven mammalian species for simultaneous environmental chemical surveillance and bioeffect monitoring (2012) Toxicology, 295, pp. 47-55; Werner, E., Heilier, K., Ducruix, C., Ezan, E., Junot, J., Tabet, J., Mass spectrometry for the identification of the discriminating signals from metabolomics: Current status and future trends (2008) Chromatogr B, 871, pp. 143-163; Jones, D.P., Park, Y., Ziegler, T.R., Nutritional metabolomics: Progress in addressing complexity in diet and health (2012) Ann Rev Nutr, 32 (118), pp. 18-20; Uppal, K., Soltow, Q., Strobel, F., Pittard, W., Gernert, K., Yu, T., XMSanalyzer: Automated pipeline for improved feature detection and downstream analysis of large-scale, non-targeted metabolomics data (2013) BMC Bioinformatics, 14, pp. 15-27; Sato, Y., Suzuki, I., Nakamura, T., Bernier, F., Aoshima, K., Oda, Y., Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology (2012) J Lipid Res, 53, pp. 567-576; Mishur, R., Rea, S., Applications of mass spectrometry to metabolomics and metabonomics: Detection of biomarkers of aging and of age-related diseases (2011) Mass Spectrom Rev, 31, pp. 70-905; Vuckovic, D., Current trends and challenges in sample preparation for global metabolomics using liquid chromatography-mass spectrometry (2012) Anal Bioanal Chem, 403, pp. 1523-1548; León, Z., García-Cañaveras, J.C., Donato, M.T., Lahoz, A., Mammalian cell metabolomics: Experimental design and sample preparation (2013) Electrophoresis, , February 22; Korman, A., Oh, A., Raskind, A., Banks, D., Statistical methods in metabolomics (2012) Evolutionary Genomics: Statistical and Computational Methods, Vol. 2, pp. 381-413. , M. Anisimova, Springer; Alexander, G.E., Chen, K., Pietrini, P., Rapoport, S.I., Reiman, E.M., Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies (2002) American Journal of Psychiatry, 159 (5), pp. 738-745. , DOI 10.1176/appi.ajp.159.5.738; Silverman, D.H.S., Small, G.W., Chang, C.Y., Lu, C.S., Kung De Aburto, M.A., Chen, W., Czernin, J., Phelps, M.E., Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome (2001) Journal of the American Medical Association, 286 (17), pp. 2120-2127; Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergstrom, M., Langstrom, B., Imaging Brain Amyloid in Alzheimer's Disease with Pittsburgh Compound-B (2004) Annals of Neurology, 55 (3), pp. 306-319. , DOI 10.1002/ana.20009; Swaminathan, S., Shen, L., Risacher, S.L., Yoder, K.K., West, J.D., Kim, S., Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort (2012) Brain Imaging Behav, 6, pp. 1-15; Greeve, I., Hermans-Borgmeyer, I., Brellinger, C., Kasper, D., Gomez-Isla, T., Behl, C., The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress (2000) J Neurosci, 20, pp. 7345-7352; Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease (2012) N Engl J Med, 367, pp. 795-804; Schwamborn, K., Caprioli, R.M., MALDI imaging mass spectrometry - Painting molecular pictures (2010) Mol Oncol, 4, pp. 529-538; Morgan, T.M., Seeley, E.H., Fadare, O., Caprioli, R.M., Clark, P.E., Imaging the clear cell renal cell carcinoma proteome (2013) J Urol, 189, pp. 1097-1103; Schober, Y., Guenther, S., Spengler, B., Römpp, A., Single cell matrix-assisted laser desorption/ionization mass spectrometry imaging (2012) Anal Chem, 84, pp. 6293-6297; Stoeckli, M., Staab, D., Staufenbiel, M., Wiederhold, K.-H., Signor, L., Molecular imaging of amyloid β peptides in mouse brain sections using mass spectrometry (2002) Analytical Biochemistry, 311 (1), pp. 33-39. , DOI 10.1016/S0003-2697(02)00386-X, PII S000326970200386X; Stoeckli, M., Chaurand, P., Hallahan, D., Caprioli, R., Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues (2001) Nat Med, 7, p. 493; Reyzer, M.L., Caprioli, R.M., MALDI-MS-based imaging of small molecules and proteins in tissues (2007) Current Opinion in Chemical Biology, 11 (1), pp. 29-35. , DOI 10.1016/j.cbpa.2006.11.035, PII S1367593106001918; Reyzer, M.L., Hsieh, Y., Ng, K., Korfmacher, W.A., Caprioli, R.M., Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry (2003) Journal of Mass Spectrometry, 38 (10), pp. 1081-1092. , DOI 10.1002/jms.525; Khatib-Shahidi, S., Andersson, M., Herman, J.L., Gillespie, T.A., Caprioli, R.M., Direct molecular analysis of whole-body animal tissue sections by imaging MALDI mass spectrometry (2006) Analytical Chemistry, 78 (18), pp. 6448-6456. , DOI 10.1021/ac060788p; Valdes-Gonzalez, T., Goto-Inoue, N., Hirano, W., Ishiyama, H., Hayasaka, T., Setou, M., New approach for glyco- and lipidomics - Molecular scanning of human brain gangliosides by TLC-Blot and MALDI-QIT-TOF MS (2011) J Neurochem, 116, pp. 678-683; Schober, Y., Schramm, T., Spengler, B., Römpp, A., Protein identification by accurate mass matrix-assisted laser desorption/ionization imaging of tryptic peptides (2011) Rapid Commun Mass Spectrom, 25, pp. 2475-2483; McDonnell, L., Heeren, R., Andren, P., Stoeckli, M., Corthals, G., Going forward: Increasing the accessibility of imaging mass spectrometry (2012) J Proteomics, 7 S, pp. 113-S125; Acquadro, E., Cabella, C., Ghiani, S., Miragoli, L., Bucci, E.M., Corpillo, D., Matrix-assisted laser desorption ionization imaging mass spectrometry detection of a magnetic resonance imaging contrast agent in mouse liver (2009) Anal Chem, 81, pp. 2779-2784; Trim, P.J., Henson, C.M., Avery, J.L., McEwen, A., Snel, M.F., Claude, E., Matrix-assisted laser desorption/ionization-ion mobility separation-mass spectrometry imaging of vinblastine in whole body tissue sections (2008) Anal Chem, 80, pp. 8628-8634; Altelaar, A.F.M., Klinkert, I., Jalink, K., De Lange, R.P.J., Adan, R.A.H., Heeren, R.M.A., Piersma, S.R., Gold-enhanced biomolecular surface imaging of cells and tissue by SIMS and MALDI mass spectrometry (2006) Analytical Chemistry, 78 (3), pp. 734-742. , DOI 10.1021/ac0513111; Nemes, P., Vertes, A., Laser ablation electrospray ionization for atmospheric pressure, in vivo, and imaging mass spectrometry (2007) Analytical Chemistry, 79 (21), pp. 8098-8106. , DOI 10.1021/ac071181r; Spengler, B., Hubert, M., Scanning microprobe matrix-assisted laser desorption ionization (SMALDI) mass spectrometry: Instrumentation for sub-micrometer resolved LDI and MALDI surface analysis (2002) Journal of the American Society for Mass Spectrometry, 13 (6), pp. 735-748. , DOI 10.1016/S1044-0305(02)00376-8, PII S1044030502003768; Koestler, M., Kirsch, D., Hester, A., Leisner, A., Guenther, S., Spengler, B., A high-resolution scanning microprobe matrix-assisted laser desorption/ionization ion source for imaging analysis on an ion trap/Fourier transform ion cyclotron resonance mass spectrometer (2008) Rapid Commun Mass Spectrom, 22, pp. 3275-3285; Pevsner, P.H., Melamed, J., Remsen, T., Kogos, A., Francois, F., Kessler, P., Mass spectrometry MALDI imaging of colon cancer biomarkers: A new diagnostic paradigm (2009) Biomarkers Med, 3, pp. 55-69; Trede, D., Schiffler, S., Becker, M., Wirtz, S., Steinhorst, K., Strehlow, J., Exploring three-dimensional matrix-assisted laser desorption/ionization imaging mass spectrometry data: Three-dimensional spatial segmentation of mouse kidney (2012) Anal Chem, 84, pp. 6079-6087; Thiele, H., Heldmann, S., Trede, D., Strehlow, J., Wirtz, S., Dreher, W., Et al., 2D and 3D MALDI-imaging: Conceptual strategies for visualization and data mining (2013) Biochim Biophys Acta, , March 4 epub; Seeley, E., Caprioli, R., MALDI imaging mass spectrometry of human tissue: Method challenges and clinical perspectives (2011) Trends Biotechnol, 29, pp. 136-143; Sinha, T.K., Khatib-Shahidi, S., Yankeelov, T.E., Mapara, K., Ehtesham, M., Cornett, D.S., Integrating spatially resolved three-dimensional MALDI. I.M.S. with in vivo magnetic resonance imaging (2008) Nat Methods, 5, pp. 57-59; Edmondson, R.D., Russell, D.H., Evaluation of matrix-assisted laser desorption ionization-time-of- flight mass measurement accuracy by using delayed extraction (1996) Journal of the American Society for Mass Spectrometry, 7 (10), pp. 995-1001. , DOI 10.1016/1044-0305(96)00027-X; Deininger, S.O., Ebert, M.P., Fütterer, A., Gerhard, M., Röcken, C., MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers (2008) J Proteome Res, 7, pp. 5230-5236; McDonnell, L.A., Corthals, G.L., Willems, S.M., Van Remoortere, A., Van Zeijl, R.J., Deelder, A.M., Peptide and protein imaging mass spectrometry in cancer research (2010) J Proteomics, 73, pp. 1921-1944; Chaurand, P., Sanders, M.E., Jensen, R.A., Caprioli, R.M., Proteomics in diagnostic pathology: Profiling and imaging proteins directly in tissue sections (2004) American Journal of Pathology, 165 (4), pp. 1057-1068; Cazares, L.H., Troyer, D., Mendrinos, S., Lance, R.A., Nyalwidhe, J.O., Beydoun, H.A., Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal- regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue (2009) Clin Cancer Res, 15, pp. 5541-5551; Meding, S., Nitsche, U., Balluff, B., Elsner, M., Rauser, S., Schone, C., Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging (2012) J Proteome Res, 11, pp. 1996-2003; Deininger, S.O., Becker, M., Suckau, D., Tutorial: Multivariate statistical treatment of imaging data for clinical biomarker discovery (2010) Mass Spectrometry Imaging: Principles and Protocols, Methods in Molecular Biology, 656, pp. 385-404. , S. Rubakhin, J. Sweedler; Miura, D., Fujimura, Y., Wariishi, H., In situ metabolomic mass spectrometry imaging: Recent advances and difficulties (2012) J Proteomics, 75, pp. 5052-5060; Kilpinen, H., Barrett, J.C., How next-generation sequencing is transforming complex disease genetics (2013) Trends Genet, 29, pp. 23-30; Dubé, J.B., Hegele, R.A., Genetics 100 for cardiologists: Basics of genome-wide association studies (2013) Can J Cardiol, 29, pp. 10-17; Bertram, L., Lill, C.M., Tanzi, R.E., The genetics of Alzheimer's disease: Back to the future (2010) Neuron, 68, pp. 270-281; Xi, R., Kim, T.-M., Park, P., Detecting structural variations in the human genome using next generation sequencing (2011) Brief Funct Genomics, 9, pp. 405-415; Hangauer, M.J., Vaughn, I.W., McManus, M.T., Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs (2013) PLoS Genet, 9, p. 1003569; Fratkin, E., Bercovici, S., Stephan, D.A., The implications of ENCODE for diagnostics (2012) Nat Biotechnol, 30, pp. 1064-1065; Tanzi, R., The genetics of Alzheimer disease (2012) Cold Spring Harb Perspect Med, 2, pp. 6296-6306; Mahley, R.W., Huang, Y., Alzheimer disease: Multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches (2009) Ann Neurol, 65, pp. 623-625; Morgan, K., Three new pathways leading to Alzheimer's disease (2011) Neuropath Appl Neurobiol, 37, pp. 353-357; Ikegawa, S., A short history of the genome-wide association study: Where we were and where we are going (2012) Genomics Inform, 10, pp. 220-225; Shyr, D., Liu, Q., Next generation sequencing in cancer research and clinical application (2013) Biol Proc Online, 15, pp. 4-15; Krebs, C.E., Paisán-Ruiz, C., The use of next-generation sequencing in movement disorders (2012) Front Genet, 3, p. 75; Gasser, T., Hardy, J., Mizuno, Y., Milestones in PD genetics (2011) Mov Disord, 26, pp. 1042-1048; Tsuji, A., Genetics of neurodegenerative diseases: Insights from high-throughput resequencing (2010) Human Molec Genetics, 19, pp. 65-R70; Lees, A., Hardy, J., Revesz, T., Parkinson's disease (2009) Lancet, 373, pp. 2055-2066; Hardy, J., Lewis, P., Revesz, T., Lees, A., Paisan-Ruiz, C., The genetics of Parkinson's syndromes: A critical review (2009) Curr Opin Genet Dev, 19, pp. 254-265; Vilariño-Güell, C., Wider, C., Ross, O.A., Dachsel, J.C., Kachergus, J.M., Lincoln, S.J., VPS35 mutations in Parkinson disease (2011) Am J Hum Genet, 289, pp. 162-167; Paisan-Ruiz, C., Dogu, O., Yilmaz, A., Houlden, H., Singleton, A., SPG11 mutations are common in familial cases of complicated hereditary spastic paraplegia (2008) Neurology, 70 (16), pp. 1384-1389. , DOI 10.1212/01.wnl.0000294327.66106.3d, PII 0000611420080415100004; Anheim, M., Lagier-Tourenne, C., Stevanin, G., Fleury, M., Durr, A., Namer, I., SPG11 spastic paraplegia. A new cause of juvenile parkinsonism (2009) J Neurol, 256, pp. 104-108; Baylin, S.B., DNA methylation and gene silencing in cancer (2005) Nat Clin Pract Oncol, 21 (SUPPL.), pp. 4-S11; Fukushige, S., Horii, A., DNA methylation in cancer: A gene silencing mechanism and the clinical potential of its biomarkers (2013) Tohoku J Exp Med, 229, pp. 173-185; De Boni, L., Tierling, S., Roeber, S., Walter, J., Giese, A., Kretzschmar, H., Next-generation sequencing reveals regional differences of the a-synuclein methylation state independent of Lewy body disease (2011) Neuromol Med, 13, pp. 310-320; Jowaed, A., Schmitt, I., Kaut, O., Wüllner, U., Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains (2010) J Neurosci, 30, pp. 6355-6359; Desplats, P., Spencer, B., Coffee, E., Patel, P., Michael, S., Patrick, C., Alpha- synuclein sequesters Dnmt1 from the nucleus: A novel mechanism for epigenetic alterations in Lewy body diseases (2011) J Biol Chem, 286, pp. 9031-9037; Matsumoto, L., Takuma, H., Tamaoka, A., Kurisaki, H., Date, H., Tsuji, S., CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease (2010) PLoS One, 5, p. 15522; Richter, J., Appenzeller, S., Ammerpohl, O., Deuschl, G., Paschen, S., Brüggemann, N., No evidence for differential methylation of α-synuclein in leukocyte DNA of Parkinson's disease patients (2012) Mov Disord, 27, pp. 590-591; Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline (2012) Nature, 488, pp. 96-99; Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., Minthon, L., Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study (2006) Lancet Neurology, 5 (3), pp. 228-234. , DOI 10.1016/S1474-4422(06)70355-6, PII S1474442206703556; Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., Alzheimer's Disease Neuroimaging Initiative Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects (2009) Ann Neurol, 65, pp. 403-413; Blennow, K., Zetterberg, H., Fagan, A., Fluid biomarkers in Alzheimer disease (2012) Cold Spring Harb Perspect Med, 2, pp. 006221-a006244; Swets, J.A., (1996) Signal Detection Theory and ROC Analysis in Psychology and Diagnostics: Collected Papers, , Lawrence Erlbaum Associates Mahwah, NJ; Dieterle, F., Sistare, F., Goodsaid, F., Papaluca, M., Ozer, J.S., Webb, C.P., Renal biomarker qualification submission: A dialog between the FDA-EMEA and Predictive Safety Testing Consortium (2010) Nat Biotech, 28, pp. 455-462; Delong, E.R., Delong, D.M., Clarke-Pearson, D.L., Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach (1988) Biometrics, 44, pp. 837-845; Pepe, M.S., Feng, Z., Janes, H., Bossuyt, P.M., Potter, J.D., Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design (2008) J Natl Cancer Inst, 100, pp. 1432-1438; Daniel, C.W., Bast, Jr.R.C., Berg, C.D., Diamandis, E.P., Godwin, A.K., Hartge, P., Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens (2011) Cancer Prev Res, 4, pp. 365-374; Srivastava, S., The early detection research network: 10-year outlook (2013) Clin Chem, 59, pp. 60-67; Zhang, J., Roebuck, P., Coombes, K.R., Simulating gene expression data to estimate sample size for class and biomarker discovery (2012) Int J Advances Life Sci, 4, pp. 44-51; Tu, W., Basic principles of statistical inference (2007) Methods Mol Biol, 404, pp. 53-72; McDermott, J.E., Wang, J., Mitchell, H., Webb-Robertson, B.J., Hafen, R., Ramey, J., Challenges in biomarker discovery: Combining expert insights with statistical analysis of complex omics data (2013) Expert Opin Med Diagn, 7, pp. 37-51; Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing (1995) J R Stat Soc, Series B, 57, pp. 289-300; Klerk, L., Broersen, A., Fletcher, I., Vanliere, R., Heeren, R., Extended data analysis strategies for high resolution imaging MS: New methods to deal with extremely large image hyperspectral datasets (2007) Int J Mass Spectrom, 260, pp. 222-236; Alexandrov, T., MALDI imaging mass spectrometry: Statistical data analysis and current computational challenges (2012) BMC Bioinformatics, 13 (SUPPL. 16), pp. 11-S24; Anderson, D.C., Li, W., Payan, D.G., Noble, W.S., A new algorithm for the evaluation of shotgun peptide sequencing in proteomics: Support vector machine classification of peptide MS/MS spectra and SEQUEST scores (2003) Journal of Proteome Research, 2 (2), pp. 137-146. , DOI 10.1021/pr0255654; Barla, A., Jurman, G., Riccadonna, S., Merler, S., Chierici, M., Furlanello, C., Machine learning methods for predictive proteomics (2008) Briefings in Bioinformatics, 9 (2), pp. 119-128. , DOI 10.1093/bib/bbn008, Computational Proteomics; Luts, J., Ojeda, F., Van De Plas, R., De Moor, B., Van Huffel, S., Suykens, J.A., A tutorial on support vector machine-based methods for classification problems in chemometrics (2010) Anal Chim Acta, 665, pp. 129-145; Kingsford, C., Salzberg, S.L., What are decision trees? (2008) Nat Biotechnol, 26, pp. 1011-1013; Diaz-Uriarte, R., Alvarez De Andres, S., Gene selection and classification of microarray data using random forest (2006) BMC Bioinformatics, 7, p. 3; O'Bryant, S.E., Xiao, G., Barber, R., Huebinger, R., Wilhelmsen, K., Edwards, M., A blood-based screening tool for Alzheimer's disease that spans serum and plasma: Findings from TARC and ADNI (2011) PLoS One, 6, p. 28092; Zhang, Z., Yu, Y., Xu, F., Berchuck, A., Van Haaften-Day, C., Havrilesky, L.J., De Bruijn, H.W.A., Bast Jr., R.C., Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer (2007) Gynecologic Oncology, 107 (3), pp. 526-531. , DOI 10.1016/j.ygyno.2007.08.009, PII S0090825807006300; Wagner, P.D., Srivastava, S., New paradigms in translational science research in cancer biomarkers (2012) Transl Res, 159, pp. 343-353; Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F.L., Wolmark, N., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer (2004) New England Journal of Medicine, 351 (27), pp. 2817-2826. , DOI 10.1056/NEJMoa041588; Heller, M.J., DNA microarray technology: Devices, systems, and applications (2002) Annual Review of Biomedical Engineering, 4, pp. 129-153. , DOI 10.1146/annurev.bioeng.4.020702.153438; Van De Vijver, M.J., He, Y.D., Van 'T Veer, L.J., Dai, H., Hart, A.A.M., Voskuil, D.W., Schreiber, G.J., Bernards, R., A gene-expression signature as a predictor of survival in breast cancer (2002) New England Journal of Medicine, 347 (25), pp. 1999-2009. , DOI 10.1056/NEJMoa021967; Van't Veer, L.J., Dai, H., Van De Vijver, M.J., He, Y.D., Hart, A.A.M., Mao, M., Peterse, H.L., Friend, S.H., Gene expression profiling predicts clinical outcome of breast cancer (2002) Nature, 415 (6871), pp. 530-536. , DOI 10.1038/415530a; Anderson, D.C., Alzheimer's disease biomarkers: More than molecular diagnostics (2013) Drug Dev Res, 74, pp. 92-111; Nagele, E., Han, M., Demarshall, C., Belinka, B., Nagele, R., Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera (2011) PLoS One, 6, pp. 23112-e23119; Carter, C., Alzheimer's disease: APP, gamma secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and their relationships with herpes simplex, C. Pneumoniae, other suspect pathogens, and the immune system (2011) Int J Alzheimers Dis, pp. 501862-501896; Colasanti, T., Barbati, C., Rosano, G., Malorni, W., Ortona, E., Autoantibodies in patients with Alzheimer's disease: Pathogenetic role and potential use as biomarkers of disease progression (2010) Autoimmun Rev, 9, pp. 807-811; O'Bryant, S.E., Xiao, G., Barber, R., Reisch, J., Doody, R., Fairchild, T., A serum protein-based algorithm for the detection of Alzheimer disease (2010) Arch Neurol, 67, pp. 1077-1081; Lemoine, B.R., Rayburn, S., Benton, R.S., Data fusion and feature selection for Alzheimer's disease (2010) Lecture Notes Comp Sci, 6334, pp. 320-327; Di Paolo, G., Kim, T.W., Linking lipids to Alzheimer's disease: Cholesterol and beyond (2011) Nat Rev Neurosci, 12, pp. 284-296; (2004) Challenge and Opportunity on the Critical Path to New Medical Products, , http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ default.htm, Food And Drug Administration US Dept. of Health and Human Services See also; Goodsaid, F.M., Frueh, F.W., Mattes, W., Strategic paths for biomarker qualification (2008) Toxicology, 245, pp. 219-223; Warnock, D., Peck, C., A roadmap for biomarker qualification (2010) Nat Biotechnol, 28, pp. 444-445; Sistare, F.D., Dieterle, F., Troth, S., Holder, D.J., Gerhold, D., Andrews-Cleavenger, D., Towards consensus practices to qualify safety biomarkers for use in early drug development (2010) Nat Biotechnol, 5, pp. 446-454; Bonventre, J., Vaidya, V., Schmouder, R., Feig, P., Dieterle, F., Next-generation biomarkers for detecting kidney toxicity (2010) Nat Biotechnol, 28, pp. 436-440; Pepe, M.S., Etzioni, R., Feng, Z., Potter, J.D., Thompson, M.L., Thornquist, M., Winget, M., Yasui, Y., Phases of biomarker development for early detection of cancer (2001) Journal of the National Cancer Institute, 93 (14), pp. 1054-1061; Feng, Z., Kagan, J., Pepe, M., Thornquist, M., Ann Rinaudo, J., Dahlgren, J., The Early Detection Research Network's specimen reference sets: Paving the way for rapid evaluation of potential biomarkers (2013) Clin Chem, 59, pp. 68-74; Amin, W., Singh, H., Dzubinski, L.A., Schoen, R.E., Parwani, A.V., Design and utilization of the colorectal and pancreatic neoplasm virtual biorepository: An early detection research network initiative (2010) J Pathol Inform, 1, pp. 22-41; Tomlins, S.A., Laxman, B., Dhanasekaran, S.M., Helgeson, B.E., Cao, X., Morris, D.S., Menon, A., Chinnaiyan, A.M., Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer (2007) Nature, 448 (7153), pp. 595-599. , DOI 10.1038/nature06024, PII NATURE06024; Kumar-Sinha, C., Tomlins, S.A., Chinnaiyan, A.M., Recurrent gene fusions in prostate cancer (2008) Nat Rev Cancer, 8, pp. 497-511; Hessels, D., Smit, F.P., Verhaegh, G.W., Witjes, J.A., Cornel, E.B., Schalken, J.A., Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer (2007) Clinical Cancer Research, 13 (17), pp. 5103-5108. , http://clincancerres.aacrjournals.org/cgi/reprint/13/17/5103, DOI 10.1158/1078-0432.CCR-07-0700; De Kok, J.B., Verhaegh, G.W., Roelofs, R.W., Hessels, D., Kiemeney, L.A., Aalders, T.W., Swinkels, D.W., Schalken, J.A., DD3PCA3, a very sensitive and specific marker to detect prostate tumors (2002) Cancer Research, 62 (9), pp. 2695-2698; Tomlins, S.A., Aubin, S.M., Siddiqui, J., Lonigro, R.J., Sefton-Miller, L., Miick, S., Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA (2011) Sci Transl Med, 3 (94), p. 72; Hoshimoto, S., Shingai, T., Morton, D.L., Kuo, C., Faries, M.B., Chong, K., Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial (2012) J Clin Oncol, 30, pp. 3819-3826; Hiltermann, T.J., Pore, M.M., Van Den Berg, A., Timens, W., Boezen, H.M., Liesker, J.J., Circulating tumor cells in small-cell lung cancer: A predictive and prognostic factor (2012) Ann Oncol, 23, pp. 2937-2942; Gorges, T.M., Pantel, K., Circulating tumor cells as therapy-related biomarkers in cancer patients (2013) Cancer Immunol Immunother, 62, pp. 931-939; Mueller, S.G., Weiner, M.W., Thal, L.J., Petersen, R.C., Jack, C.R., Jagust, W., Trojanowski, J.Q., Beckett, L., Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI) (2005) Alzheimer's and Dementia, 1 (1), pp. 55-66. , DOI 10.1016/j.jalz.2005.06.003, PII S155252600500004X; Weiner, M.W., Aisen, P.S., Jack, Jr.C.R., Jagust, W.J., Trojanowski, J.Q., Shaw, L., Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's disease neuroimaging initiative: Progress report and future plans (2010) Alzheimer's Dementia, 6, pp. 202-211. , e7; Weiner, M.W., Veitch, D.P., Aisen, P.S., Beckett, L.A., Cairns, N.J., Green, R.C., Alzheimer's Disease Neuroimaging Initiative, the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception (2012) Alzheimer's Dementia, 8 (1 SUPPL.), pp. 1-S68; Jack, Jr.C.R., Bernstein, M.A., Borowski, B.J., Gunter, J.L., Fox, N.C., Thompson, P.M., Alzheimer's Disease Neuroimaging Initiative. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative (2010) Alzheimer's Dementia, 6, pp. 212-220; Jack, Jr.C.R., Vemuri, P., Wiste, H., Weigand, S., Lesnick, T., Shapes of the trajectories of five major biomarkers of Alzheimer's disease (2012) Arch Neurol, 69, pp. 857-867; Galasko, D., Klauber, M.R., Hofstetter, C.R., Salmon, D.P., Lasker, B., Thal, L.J., The mini-mental state examination in the early diagnosis of Alzheimer's disease (1990) Archives of Neurology, 47 (1), pp. 49-52; Jack, Jr.C.R., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010) Lancet Neurol, 9, pp. 119-128; Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease (2012) N Engl J Med, 367, pp. 795-804; Thies, W., Bleiler, L., Alzheimer's disease facts and figures (2011) Alzheimer's Dementia, 7, pp. 208-244; Jedynak, B., Lang, A., Liu, B., Katz, E., Zhang, Y., A computational ADNI datasets have been used to examine general features of this model (2012) Neuroimage, 63, pp. 1478-1486; Han, S.D., Gruhl, J., Beckett, L., Dodge, H., Stricker, N., Beta amyloid, tau, neuroimaging, and cognition: Sequence modeling of biomarkers for Alzheimer's Disease (2012) Brain Imaging Behav, 6, pp. 610-620; Cui, Y., Liu, B., Luo, S., Zhen, X., Fan, M., Alzheimer's Disease Neuroimaging Initiative Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors (2011) PLoS One, 6, p. 21896; Liu, Y., Mattila, J., Á, R.M., Paajanen, T., Koikkalainen, J., Van Gils, M., Alzheimer's Disease Neuroimaging Initiative. Predicting AD conversion: Comparison between prodromal AD guidelines and computer assisted PredictAD tool (2013) PLoS One, 8, p. 55246; Zhang, D., Shen, D., Alzheimer's Disease Neuroimaging Initiative. Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers (2012) PLoS One, 7, p. 33182; Price, J.L., Morris, J.C., Tangles and plaques in nondemented aging and 'preclinical' alzheimer's disease (1999) Annals of Neurology, 45 (3), pp. 358-368. , DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Bossuyt, P.M., Reitsma, J.B., Bruns, D.E., Gatsonis, C.A., Glasziou, P.P., Irwig, L.M., Lijmer, J.G., De Vet, H.C.W., Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative (2003) Clinical Chemistry, 49 (1), pp. 1-6. , DOI 10.1373/49.1.1; Goodsaid, F., Frueh, F., Process map proposal for the validation of genomic biomarkers (2006) Pharmacogenomics, 7 (5), pp. 773-782. , http://www.futuremedicine.com/doi/full/10.2217/14622416.7.5.773, DOI 10.2217/14622416.7.5.773; Simon, R., Clinical trials for predictive medicine (2012) Statist Med, 31, pp. 3031-3040; Matsui, S., Genomic biomarkers for personalized medicine: Development and validation in clinical studies (2013) Comp Math Methods Med, , article ID 865980; Mandrekar, S., An, M., Sargent, D., A review of phase II trial designs for initial marker validation (2013) Contemp Clin Trials, , May 8; Kern, S., Why your new cancer biomarker may never work: Recurrent patterns and remarkable diversity in biomarker failures (2012) Cancer Res, 72, pp. 6097-6101; Ioannidis, J., Biomarker failures (2013) Clin Chem, 59, pp. 202-204; Srivastava, S., Cancer biomarker discovery and development in gastrointestinal cancers: Early detection research network - A collaborative approach (2007) Gastrointestinal Cancer Res, 1 (SUPPL. 2), pp. 60-S63; Burton, A., Big science for a big problem: ADNI enters its second phase (2011) Lancet Neurol, 10, pp. 206-207; Becker, R.E., Greig, N.H., Alzheimer's disease drug development: Old problems require new priorities (2008) CNS Neurol Disord Drug Targets, 7, pp. 499-511; Friedlin, B., McShane, L., Korn, E., Randomized clinical trials with biomarkers: Design issues (2010) J Natl Cancer Inst, 102, pp. 152-160; Ransohoff, D.F., Bias as a threat to the validity of cancer molecular-marker research (2005) Nature Reviews Cancer, 5 (2), pp. 142-149. , DOI 10.1038/nrc1550; Jacobs, I., Menon, U., The Sine Qua Non of discovering novel biomarkers for early detection of ovarian cancer: Carefully selected preclinical samples (2011) Cancer Prev Res, 4, pp. 299-302; Cramer, D.W., Bast, Jr.R.C., Berg, C.D., Diamandis, E.P., Godwin, A.K., Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens (2011) Cancer Prev Res, 4, pp. 365-374; Zhu, C.S., Pinsky, P.F., Cramer, D.W., Ransohoff, D., Hartage, P., A Framework for evaluating biomarkers for early detection: Validation of biomarker panels for ovarian cancer (2011) Cancer Prev Res, 4, pp. 375-383; Bradbury, S., Jakoby, W., Glycerol as an enzyme-stabilizing agent: Effects on aldehyde dehydrogenase (1972) Proc Nat Acad Sci USA, 69, pp. 2373-2376; Harris, Jr.G.C., Sweeney, M.J., Changes in the protein concentration of chicken seminal plasma after rapid freeze-thaw (1970) Cryobiology, 7, pp. 209-215; Pikal-Cleland, K.A., Rodriguez-Hornedo, N., Amidon, G.L., Carpenter, J.F., Protein denaturation during freezing and thawing in phosphate buffer systems: Monomeric and tetrameric β-galactosidase (2000) Archives of Biochemistry and Biophysics, 384 (2), pp. 398-406. , DOI 10.1006/abbi.2000.2088; Cao, E., Chen, Y., Cui, Z., Foster, P.R., Effect of freezing and thawing rates on denaturation of proteins in aqueous solutions (2003) Biotechnology and Bioengineering, 82 (6), pp. 684-690. , DOI 10.1002/bit.10612; (2004) Affymetrix, Sample Pooling for Microarray Analysis: A Statistical Assessment of Risks and Biases, , Technical Note, no. 701494 Rev. 2; Sadiq, S., Agranoff, D., Pooling serum samples may lead to loss of potential biomarkers in SELDI-ToF MS proteomic profiling (2008) Proteome Sci, 6, pp. 16-23; Telaar, A., Nurnberg, G., Repsilber, D., Finding biomarker signatures in pooled sample designs: A simulation framework for methodological comparisons (2010) Adv Bioinf, p. 318473; Anderson, N.L., Anderson, N.G., The human plasma proteome: History, character, and diagnostic prospects (2002) Mol Cell Proteomics, 1, pp. 845-867; Shi, T., Zhou, J.Y., Gritsenko, M.A., Hossain, M., Camp II, D.G., Smith, R.D., IgY14 and SuperMix immunoaffinity separations coupled with liquid chromatography-mass spectrometry for human plasma proteomics biomarker discovery (2012) Methods, 56, pp. 246-253; Tu, C., Rudnick, P.A., Martinez, M.Y., Cheek, K.L., Stein, S.E., Slebos, R.J., Depletion of abundant plasma proteins and limitations of plasma proteomics (2010) J Proteome Res, 9, pp. 4982-4991; Surinova, S., Schiess, R., Huttenhain, R., Cerciello, F., Wollscheid, B., Aebersold, R., On the development of plasma protein biomarkers (2010) J Proteome Res, 10, pp. 5-16; Cray, C., Acute phase proteins in animals (2012) Prog Mol Biol Transl Sci, 105, pp. 113-150; Cray, C., Zaias, J., Altman, N.H., Acute phase response in animals: A review (2009) Comp Med, 59, pp. 517-526; Ceron, J.J., Eckersall, P.D., Martinez-Subiela, S., Acute phase proteins in dogs and cats: Current knowledge and future perspectives (2005) Veterinary Clinical Pathology, 34 (2), pp. 85-99; Leek, J.T., Scharpf, R.B., Bravo, H.C., Simcha, D., Langmead, B., Johnson, W.E., Tackling the widespread and critical impact of batch effects in high-throughput data (2010) Nat Rev Genet, 11, pp. 733-739; Hu, J., Coombes, K.R., Morris, J.S., Baggerly, K.A., The importance of experimental design in proteomic mass spectrometry experiments: Some cautionary tales (2005) Briefings in Functional Genomics and Proteomics, 3 (4), pp. 322-331. , DOI 10.1093/bfgp/3.4.322; Baggerly, K.A., Coombes, K.R., Neeley, E.S., Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer (2008) J Clin Oncol, 26, pp. 1187-1188. , 1186-7; author reply; Kyzas, P.A., Loizou, K.T., Ioannidis, J.P.A., Selective reporting biases in cancer prognostic factor studies (2005) Journal of the National Cancer Institute, 97 (14), pp. 1043-1055. , DOI 10.1093/jnci/dji184; Potti, A., Dressman, H.K., Bild, A., Riedel, R.F., Chan, G., Sayer, R., Cragun, J., Nevins, J.R., Genomic signatures to guide the use of chemotherapeutics (2006) Nature Medicine, 12 (11), pp. 1294-1300. , DOI 10.1038/nm1491, PII NM1491; Potti, A., Dressman, H.K., Bild, A., Riedel, R.F., Chan, G., Sayer, R., Retraction: Genomic signatures to guide the use of chemotherapeutics (2011) Nat Med, 17, p. 135; Baggerly, K.A., Coombes, K.R., Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology (2009) Annal Appl Statistics, 3, pp. 1309-1334; Baggerly, K.A., Coombes, K.R., What information should be required to support clinical "omics" publications? (2011) Clin Chem, 57, pp. 688-690; Michiels, S., Koscielny, S., Hill, C., Prediction of cancer outcome with microarrays: A multiple random validation strategy (2005) Lancet, 365 (9458), pp. 488-492. , DOI 10.1016/S0140-6736(05)17866-0; Fossel, E.T., Carr, J.M., McDonagh, J., Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma (1986) New England Journal of Medicine, 315 (22), pp. 1369-1376; Shulman, R., NMR-another cancer-test disappointment (1990) New Engl J Med, 322, pp. 1002-1003; Okunieff, P., Zietman, A., Kahn, J., Singer, S., Neuringer, L.J., Levine, R.A., Evans, F.E., Lack of efficacy of water-suppressed proton nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors (1990) New England Journal of Medicine, 322 (14), pp. 953-958; Maecker, H., Lindstrom, T., Robinson, W., Utz, P., Hale, M., New tools for classification and monitoring of autoimmune diseases (2012) Nat Rev Rheumatol, 8, pp. 317-328; Hayes, D., Paoletti, C., Circulating tumour cells: Insights into tumour heterogeneity (2013) J Intern Med, 274, pp. 137-143; Krishnamurthy, S., Bischoff, F., Ann Mayer, J., Wong, K., Pham, T., Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer (2013) Cancer Med, 2, pp. 226-233; Pestrin, M., Bessi, S., Galardi, F., Truglia, M., Biggeri, A., Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients (2009) Breast Cancer Res Treat, 118, pp. 523-530
URL: http://www.scopus.com/inward/record.url?eid=2-s2.0-84892374338&partnerID=40&md5=0551c412602440206bc24520dce63b9a
Author Address: Center for Advanced Drug Research, SRI International, Harrisonburg, VA 22802, United States
Departments of Biology, and Chemistry and Biochemistry, James Madison University, Harrisonburg, VA 22802, United States


